Here’s what researchers found:
1. Lenvatinib was the first agent to demonstrate statistical non-inferiority against sorafenib concerning overall survival rates, 13.6 months compared to 12.3 months.
2. Lenvatinib showed statistically improvements in median progression-free survival rates (7.4 months to sorafenib’s 3.4 months); time to progression (8.9 months to sorafenib’s 3.7 months) and objective response rate (24 percent to sorafenib’s 9 percent).
3. Researchers evaluated quality of life via questionnaire. Lenvatinib delayed quality of life deterioration. The five most common adverse events were hypertension, diarrhea, decreased appetite, weight loss and fatigue.
Eisai will submit regulatory applications in Japan, the U.S. and Europe during the first half of fiscal year 2017. It’ll submit an application to China in the second half of FY 2017.
More articles on gastroenterology:
Limited helminth-delivered immunotherapy shows promise for inflammatory bowel disease — 4 study insights
GI leader to know: Dr. Shirish Amin of Digestive Health Center of Indiana
3 strategies from 3 GI leaders to ease the post-fellowship transition
